Engineered 'tails' tame killer T cells for immunotherapy
Fusing a molecular tail onto the engineered T cells used in immunotherapy can inhibit their proclivity to attack each other, say researchers.
Stay updated with breaking news from Sidi Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fusing a molecular tail onto the engineered T cells used in immunotherapy can inhibit their proclivity to attack each other, say researchers.
A new Yale study has identified a way to tame the self-destructive tendencies of certain killer T cells that are used to treat cancer.
In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient’s T cells are engineered to better recognize and attack antigens on the surface of cancer cells. In treatments currently approved for use in battling lymphoma and leukemia, however, the therapy has a drawback: Amidst the cancer-killing frenzy, many engineered T cells become tainted with the remnants of cancer antigens, which causes them to turn on other T cells. This eventually depletes the body of cancer-fighting cells and opens the door for a recurrence of cancer. A new Yale study, how...
In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.
WEST HAVEN, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--Jul 27, 2023--